Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07624071 | A Study to Evaluate ALN-6222 in Participants With Obesity | PHASE1 | NOT YET_RECRUITING | 88 | — | — | Jun 3, 2026 | Dec 14, 2027 | Jun 3, 2026 | 1 | Canada |
| Arm | Type | Description |
|---|---|---|
| ALN-6222 | EXPERIMENTAL | Participants will be administered a single dose of ALN-6222. |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered a single dose of placebo. |
| Name | Type | Description |
|---|---|---|
| ALN-6222 | DRUG | ALN-6222 will be administered subcutaneously (SC). |
| Placebo | DRUG | Placebo will be administered SC. |
Inclusion Criteria - * Is an adult patient with a body mass index ≥30 kg/m\^2 to \<40 kg/m\^2 * Has a hemoglobin A1c \<6.5% Exclusion Criteria - * Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>1.5 times the upper limit of normal (ULN) * Has known human immunodeficiency ...